Last reviewed · How we verify
PF-04950615 Dose A
At a glance
| Generic name | PF-04950615 Dose A |
|---|---|
| Sponsor | Pfizer |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Pharmacokinetics And Relative Bioavailability Of Bococizumab (PF-04950615; RN316) When Administered To The Abdomen, Thigh Or Upper Arm (PHASE1)
- Dose Ranging Study Of Bococizumab (PF-04950615; RN316) In Hypercholesterolemic Japanese Subjects (PHASE2)
- Safety And Tolerability Of Multiple Doses Of PF-04950615 (RN316) In Subjects With Hypercholesterolemia (PHASE1)
- A Study To Assess The Safety Of PF-05335810 In Hypercholesterolemic Subjects (PHASE1)
- A Pharmacokinetic and Pharmacodynamic Study of PF-04950615 (RN316) in Subjects With Hypercholesterolemia (PHASE1)
- Pharmacokinetic And Pharmacodynamic Study Of A Single-Dose Of PF-04950615 (RN316) In Combination With Atorvastatin (PHASE1)
- Monthly And Twice Monthly Subcutaneous Dosing Of PF-04950615 (RN316) In Hypercholesterolemic Subjects On A Statin (PHASE2)
- A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PF-04950615 Dose A CI brief — competitive landscape report
- PF-04950615 Dose A updates RSS · CI watch RSS
- Pfizer portfolio CI